Labcorp’s testing capabilities are getting a little broader with the $237.5 million acquisition of certain laboratory assets from BioReference Health, a subsidiary of Opko Health. The BioReference ...

Labcorp forecast lower annual revenue growth for its contract research unit on Tuesday, as a prolonged funding crunch continues to weigh on its early-stage drug development clients.

Q3 2025 Earnings Call Transcript October 28, 2025 Labcorp Holdings Inc. beats earnings expectations. Reported EPS is $4.18, ...

The deal includes outreach laboratory services in 13 states. CHS will continue to operate its inpatient and emergency department labs along with other hospital-based testing services. Like its chief ...

Management cited the divestiture and consolidation of non-core early development sites, resulting in a reduction of ...